Fortress Biotech, Inc. (FBIO): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of FBIO were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Fortress Biotech
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns FBIO
55 funds and institutions reported FBIO shares worth $17.9M at the end of Q2 2026. The largest holder is Vanguard Capital Management LLC with $3.2M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 1.04M | – | $3.2M | +7% |
| Opaleye Management Inc. | 890,000 | – | $2.7M | -15% |
| Mackenzie Financial Corp | 555,676 | – | $1.7M | New |
| Gsa Capital Partners LLP | 458,472 | – | $1.4M | +80% |
| Shikiar Asset Management Inc | 305,469 | – | $935K | No change |
| Geode Capital Management, LLC | 300,521 | – | $920K | +4% |
| BlackRock, Inc. | 224,782 | – | $688K | +14% |
| Two Sigma Investments, LP | 213,786 | – | $654K | +9% |
| Bridgeway Capital Management, LLC | 177,368 | – | $543K | -3% |
| Vanguard Fiduciary Trust Co | 166,371 | – | $509K | +17% |
| HB Wealth Management, LLC | 116,675 | – | $357K | -3% |
| Kestra Advisory Services, LLC | 116,235 | – | $356K | -10% |
| Acadian Asset Management LLC | 107,303 | – | $327K | +165% |
| State Street Corp | 101,601 | – | $311K | No change |
| Goldman Sachs Group Inc | 96,358 | – | $295K | New |
| Integrated Wealth Concepts LLC | 90,400 | – | $277K | +100% |
| Renaissance Technologies LLC | 86,390 | – | $264K | -13% |
| Citadel Advisors LLC | 77,065 | – | $236K | -57% |
| Integrated Quantitative Investments LLC | 68,692 | – | $210K | New |
| Panagora Asset Management Inc | 66,025 | – | $202K | +17% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No FBIO insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
FBIO short interest
4.61M FBIO shares are sold short. Over the last 12 reports the number of shares short went down 6%.
As of Oct 30, 2026, 4.61M FBIO shares were sold short, up 2.0% from the report before. At the average daily volume of 195,478 shares, buying them all back would take about 23.6 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.61M | – | +2% | 195,478 | 23.6 |
| Oct 15, 2026 | 4.52M | – | -8% | 281,033 | 16.1 |
| Sep 30, 2026 | 4.90M | – | -4% | 266,430 | 18.4 |
| Sep 15, 2026 | 5.11M | – | -6% | 269,219 | 19.0 |
| Aug 31, 2026 | 5.44M | – | -2% | 454,930 | 12.0 |
| Aug 14, 2026 | 5.58M | – | -4% | 973,819 | 5.7 |
| Jul 31, 2026 | 5.78M | – | +8% | 481,097 | 12.0 |
| Jul 15, 2026 | 5.38M | – | +1% | 647,819 | 8.3 |
| Jun 30, 2026 | 5.31M | – | +3% | 627,060 | 8.5 |
| Jun 15, 2026 | 5.14M | – | +1% | 466,730 | 11.0 |
| May 29, 2026 | 5.09M | – | +4% | 450,027 | 11.3 |
| May 15, 2026 | 4.88M | – | +5% | 336,274 | 14.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Fortress Biotech company events
Fortress Biotech filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 1, 2026.
- Oct 1, 2026AnnouncementAs previously disclosed, on July 25, 2024, Fortress Biotech, Inc., as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “ Oaktree Agreement ”) with Oaktree Fund Administration, LLC and the lenders from time-to-time… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 23, 2026VoteReported shareholder vote results. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 30, 2026AnnouncementFortress Biotech, Inc. issued a press release announcing the closing of the sale by Cyprium Therapeutics, Inc., a majority-owned subsidiary of the Company, of its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds pursuant to the previously disclosed definitive asset… Filing
- Feb 23, 2026AgreementCyprium Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech, Inc., entered into a definitive asset purchase agreement pursuant to which Cyprium agreed to sell a Rare Pediatric Disease Priority Review Voucher. Filing
- Jan 13, 2026AnnouncementFortress Biotech, Inc. issued a press release announcing that the U.S. Food and Drug Administration approved ZYCUBO® (copper histidinate, formerly known as CUTX-101) for the treatment of Menkes disease in pediatric patients . A Rare Pediatric Disease Priority Review Voucher was issued in connection… Filing
- Dec 15, 2025AgreementFortress Biotech, Inc., as borrower, entered into the First Amendment to Credit Agreement, which amends that certain Credit Agreement dated July 25, 2024 with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “ Agent ”), and the lenders from time to time party… Filing
- Dec 15, 2025AnnouncementFortress Biotech, Inc. issued a press release announcing that the U.S. Food and Drug Administration accepted the resubmission of the New Drug Application for CUTX-101 as a Class 1 resubmission and provided a Prescription Drug User Fee Act (PDUFA) target action date of January 14, 2026 for the NDA.… Filing
- Nov 17, 2025AnnouncementAs previously disclosed, on October 1, 2025, Fortress Biotech, Inc. and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that the U.S. Food and Drug Administration had issued a Complete Response Letter relating to the New Drug Application for CUTX-101 (copper histidinate)… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Fortress Biotech financials
Famous investors that hold FBIO
2 of the 50 well-known investors we track reported holding FBIO in their latest 13F filing. The largest position is Israel Englander's, worth $4.6M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 2.17M | $4.6M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 169,109 | $362K | 0.0% | +119% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named FBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 29, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 6.5% |
| Oct 29, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 6.5% |
Questions about Fortress Biotech, Inc. (FBIO) stock
Who owns the most FBIO stock?
The largest reported owner of Fortress Biotech, Inc. (FBIO) is Vanguard Capital Management LLC. In total, 55 funds and institutions reported holding FBIO at the end of Q2 2026. See the largest owners.
Are FBIO insiders buying or selling?
No FBIO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in FBIO?
As of Oct 30, 2026, 4.61M FBIO shares were sold short, up 2.0% from the report before. At the average daily volume of 195,478 shares, buying them all back would take about 23.6 trading days (days to cover). See the history.
Which famous investors hold FBIO?
2 of the 50 well-known investors we track reported FBIO in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $4.6M. See all holders.
Executive pay
Fortress Biotech's chief executive was paid a total of $2.9M for the year ended Dec 31, 2025, up 109% from $1.4M the year before. In the last 12 months, Fortress Biotech's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.